Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D. as Senior Vice President

Neurocrine Biosciences Welcomes Andrew Ratz, Ph.D.

Neurocrine Biosciences, a prominent biopharmaceutical company dedicated to neuroscience, has officially announced the addition of Andrew Ratz, Ph.D., to its leadership team as the Senior Vice President of Drug Development, Delivery, and Device. This strategic move signals an exciting phase for the company, as Dr. Ratz steps into a role aimed at enhancing Neurocrine's research and development capabilities.

With an extensive background spanning over 28 years at Eli Lilly and Company, Dr. Ratz brings a wealth of knowledge and expertise to Neurocrine. During his tenure at Lilly, he played a pivotal role in the successful development and registration of more than 25 pharmaceutical products across various therapeutic areas. His most recent position was as Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization at Lilly. In this role, he was instrumental in leading the integrated design and development of drug-device combination products as well as packaging systems, reinforcing the importance of innovation in drug delivery mechanisms.

Dr. Ratz's extensive experience also includes serving as Senior Director of Process Chemistry and Chemical Engineering, where he oversaw global outsourcing for Lilly's small molecule portfolio. His broad skill set and leadership experience are set to significantly influence the direction of Neurocrine’s Chemistry, Manufacturing, and Controls organization. This transformation is essential as Neurocrine continues to expand its R&D portfolio and address pressing needs in the market for effective treatments.

“Andy brings unparalleled leadership and experience to Neurocrine's R&D team,” stated Neurocrine Biosciences Chief Scientific Officer Jude Onyia, Ph.D. “He joins at a critical and exciting time as we seek to discover and develop the next generation of treatments for patients with urgent needs.” Dr. Onyia's assertion reflects the company's commitment to advancing innovative solutions for complex neurological conditions, an area where Neurocrine has established itself as a leader.

In his own words, Dr. Ratz expressed, “My love of science, coupled with a passion for helping people, has always driven my professional journey. The opportunity to be part of Neurocrine, where innovation meets a commitment to improving lives, is truly inspiring. I am excited to contribute to the groundbreaking work being done here and to make a lasting impact on patients’ lives through science and discovery.” This sentiment embodies the vision and mission that drives Neurocrine’s operational strategies—dedication to improving patient outcomes through pioneering scientific advancements.

Dr. Ratz's impressive educational background includes a Bachelor of Science degree in Chemistry from Indiana University and a Ph.D. in Chemistry from Harvard University. With such strong academic credentials paired with his extensive industry experience, he is well-positioned to lead Neurocrine in its innovative ventures within the biopharmaceutical landscape.

About Neurocrine Biosciences: Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company with a straightforward mission: to alleviate suffering for people with significant medical needs. The company specializes in discovering and developing transformative treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. Currently, Neurocrine boasts a diverse portfolio, including FDA-approved therapies for conditions such as tardive dyskinesia and Huntington's disease. Its extensive pipeline showcases multiple compounds in various stages of clinical development, demonstrating a robust commitment to advancing medical science.

For three decades, Neurocrine has leveraged its deep understanding of neuroscience and the intricate connections between the brain and body to develop treatments for complex conditions. This shared knowledge fuels the company’s relentless pursuit of medicines that can relieve the burden of debilitating diseases and improve patients’ quality of life.

To find out more about Neurocrine Biosciences and its endeavors in pioneering treatments, visit neurocrine.com. Follow the company on social media platforms such as LinkedIn and X (formerly Twitter) for updates and news regarding their latest developments in medical science.